Olema Pharmaceuticals Inc. – Material Contracts Watch

EX-10.4

from 10-Q 70 pages Lease Kilroy Oyster Point Kr Oyster Point II, LLC, a Delaware Limited Liability Company, as Landlord, and Olema Pharmaceuticals, Inc., a Delaware Corporation, as Tenant

12/34/56

EX-10.3

from 10-Q 3 pages Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

12/34/56

EX-10.1

from 8-K 13 pages January 27, 2026 Shane Kovacs via Email Dear Shane: This Letter Sets Forth the Terms of the Separation and Consulting Agreement (The “Agreement”) That Olema Pharmaceuticals, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1. Separation. Your Last Day of Work With the Company and Your Employment Termination Date Will Be January 30, 2026 (The “Separation Date”)

12/34/56

EX-10.1

from 10-Q 4 pages Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

12/34/56

EX-10.1

from 10-Q 4 pages Olema Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

12/34/56

EX-10.27

from 10-K 3 pages Amendment Number No. 2 to Drug Discovery Collaboration and License Agreement

12/34/56

EX-10.26

from 10-K 3 pages Amendment Number No. 1 to Drug Discovery Collaboration and License Agreement

12/34/56

EX-10.25

from 10-K 63 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential. Information That Was Omitted Has Been Noted in This Document With a Placeholder Identified by the Mark “[***]”. Clinical Trial Collaboration and Supply Agreement

12/34/56

EX-10.18

from 10-K 10 pages January 27, 2025 Shawnte Mitchell Email/Docusign Re: Employment Terms 1

12/34/56

EX-10.14

from 10-K 27 pages Olema Pharmaceuticals, Inc. 2022 Inducement Plan Adopted by the Board of Directors: January 19, 2022 Amended by the Compensation Committee of the Board of Directors: December 5, 2024 Effective: January 1, 2025

12/34/56

EX-10.1

from 8-K 49 pages Olema Pharmaceuticals, Inc. Securities Purchase Agreement

12/34/56

EX-10.2

from 10-Q 4 pages Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy

12/34/56

EX-10.1

from 10-Q 6 pages Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement

12/34/56

EX-10.1

from 8-K 5 pages Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement

12/34/56

EX-10.1

from 8-K 28 pages Olema Pharmaceuticals, Inc. Stock Purchase Agreement

12/34/56

EX-10.3

from 10-Q 8 pages March 8, 2023 ​ Kinney Horn via Email ​ Dear Kinney: This Letter Sets Forth the Substance of the Separation and Consulting Agreement (The “Agreement”) That Olema Pharmaceuticals, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1.separation. Your Employment Termination Date Will Be March 24, 2023 (The “Separation Date”)

12/34/56

EX-10.2

from 10-Q 8 pages March 21, 2023 Cyrus Harmon via Email ​ Dear Cyrus: This Letter Sets Forth the Substance of the Separation Agreement (The “Agreement”) That Olema Pharmaceuticals, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1.separation. Your Employment Termination Date Will Be March 24, 2023 (The “Separation Date”). Notwithstanding the Termination of Your Employment Relationship, You Will Remain a Member of the Company’s Board of Directors (The “Board”)

12/34/56

EX-10.1

from 10-Q 42 pages Preliminary Statements

12/34/56

EX-10.1

from 10-Q 51 pages Drug Discovery Collaboration and License Agreement

12/34/56

EX-10.19

from 10-K 9 pages ​ December 15, 2021 ​ Naseem Zojwalla, M.D. via Email/Docusign ​ Re:employment Terms ​ Dear Naseem: ​ Olema Pharmaceuticals, Inc. (The “Company”) Is Pleased to Offer You Employment as Its Chief Medical Officer, Pursuant to the Terms of This Offer Letter Agreement (The “Agreement”). ​

12/34/56